Pfizer establishes new US research network
pharmafile | November 17, 2010 | News story | Research and Development, Sales and Marketing | BiodiscoveryTherapeutics, MedImmune, Pfizer
Pfizer has established a new network of research partnerships with its Global Centers for Therapeutic Innovation.
The Centers is a network of partnerships with leading academic medical centres that aim toward accessing translational researchers.
The University of California, San Francisco, is set to be its first collaboration.
Pfizer said it expects to establish local Centers at each partner site that enable Pfizer and academic medical centre teams to work ‘side-by-side’.
The US-based pharma firm will also make available its proprietary antibody libraries and advanced research tools, along with technical support across the development process.
In addition to funding clinical programmes, Pfizer will offer its partners equitable intellectual property and ownership rights to support continued research, as well as broad rights to publication with additional milestone payments and royalties.
In return, Pfizer will have the opportunity to potentially broaden its pipeline with novel and highly differentiated candidate drugs to treat diseases of unmet medical need.
Anthony Coyle, former VP and global head of respiratory, inflammation, and autoimmune research at MedImmune will head the Centres that will be headquartered in Cambridge, Massachusetts.
Jose-Carlos Gutierrez-Ramos, Ph.D., Pfizer’s senior VP of worldwide BioTherapeutics research and development, said: “With his keen sense of biotechnology culture, strong scientific leadership and history of building successful collaborations, Anthony Coyle is the ideal person to lead the Centers for Therapeutic Innovation.
“This new model complements the venture capitalist – funded biotech start up and has the potential to catalyse the transformation of global biomedical drug discovery by advancing scientific breakthroughs in translational medicine.”
Mikael Dolsten, M.D., Ph.D., president of Pfizer worldwide research & development, said: “The Centers for Therapeutic Innovation represent a truly novel open innovation paradigm, combining the unique advantages of top academic research institutions with Pfizer’s leading drug development capabilities and research technologies.
“We are excited to pioneer this approach to seek to translate science into novel proofs of mechanism in a more efficient and accelerated manner to better serve patients.”
Jeffrey A. Bluestone, Ph.D., UCSF executive vice chancellor and provost, said: “This is an excellent example of how we can fundamentally improve the process of translating research into better drugs by bringing all of the people involved to the same table.”
In a statement Pfizer said that the Centers will initially focus on collaborations within the US and build the network at other US-based medical institutions but expects to expand into Europe and Asia in 2012.
Ben Adams
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
